The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
- Resource Type
- Review Article
- Source
- In
Critical Reviews in Oncology / Hematology March 2015 93(3):190-202 - Subject
- Language
- ISSN
- 1040-8428